Canagliflozin is a sodium-glucose linked-transport 2 (SGLT2) receptor inhibitor newly approved for the treatment of type 2 diabetes mellitus (T2DM). Under normal conditions, the SGLT2 receptor in the proximal tubule resorbs filtered glucose until its resorptive capacity is reached, which is a mechanism that accounts for more than 90% of renal glucose reabsorption . Inhibitors of the SGLT2 receptor reduce glucose reabsorption and promote glycosuria and osmotic diuresis. As such, this agent promotes glycemic control and caloric loss with a mechanism independent of insulin. A novel medication introduced in 2013, canagliflozin is effective in improving haemoglobin A1c levels without the adverse effects associated with insulin and insulin-related agents. Given its unique mechanism of action and distinct side effect profile, it is important to consider the optimal clinical situations for its use.
Internal Medicine Open Access, an official journal of OMICS International publishes all the articles related to Canagliflozin . The journal is subjecting all the received manuscripts to a strict peer review process. The articles published in the journal are Open Access i.e, freely accessible to readers all around the world. Internal Medicine Open Access is maintaining the quality of articles through its strict peer review process.
Last date updated on May, 2021